$ 4.01
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of MDXH is 5.9 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
